Stability of fosfomycin and qninolones in peritoneal dialysis solution

Quentin, Claudine; Bouchet, J L; Gaillard, Isabelle; Bébéar, Christiane

doi:10.1093/jac/25.5.878

Cited by 8 publications

(6 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…This is the first investigation on the antibacterial activity of the drug combination. However, previous studies confirmed the preserved antibacterial activity and stability of fosfomycin in different peritoneal dialysis fluids with bioassays [32,33]. Furthermore, our HPLC-MS analysis confirmed that degradation was neither present for the drugs alone nor in the drug combination solutions during 24 h. Previously, only an unchanged concentration of fosfomycin after mixture with four different peritoneal fluids has been confirmed with HPLC-MS analysis [32].…”

Section: Discussionsupporting

confidence: 77%

The Combination of Fosfomycin, Metronidazole, and Recombinant Human Granulocyte-Macrophage Colony-Stimulating Factor is Stable in vitro and Has Maintained Antibacterial Activity

et al. 2017

View full text Add to dashboard Cite

show abstract

Section: Discussionsupporting

confidence: 77%

The Combination of Fosfomycin, Metronidazole, and Recombinant Human Granulocyte-Macrophage Colony-Stimulating Factor is Stable in vitro and Has Maintained Antibacterial Activity

et al. 2017

View full text Add to dashboard Cite

show abstract

“…Before the clinical use of intraperitoneal fosfomycin, however, it is important to ensure compatibility of the antibiotic agent with PDFs in which the drug is administered. Quentin et al [ 14 ] investigated the stability of fosfomycin in the 1.36% glucose containing PDF Dianeal ® . Drug concentrations were determined by the use of a microbiological assay and fosfomycin was found to be stable (drug decomposition less than 10%) at room temperature over 24 h .…”

Section: Discussionmentioning

confidence: 99%

Compatibility of fosfomycin with different commercial peritoneal dialysis solutions

Kussmann

Baumann

Hauer

et al. 2017

Eur J Clin Microbiol Infect Dis

View full text Add to dashboard Cite

For treatment of peritoneal dialysis-related peritonitis, intraperitoneal administration of antibiotics remains the preferable route. For home-based therapy, patients are commonly supplied with peritoneal dialysis fluids already containing antimicrobial agents. The present study set out to investigate the compatibility of fosfomycin with different peritoneal dialysis fluids, namely, Extraneal®, Nutrineal®, Physioneal® 1.36% and Physioneal® 2.27%, under varying storage conditions. The peritoneal dialysis fluid bags including 4 g fosfomycin were stored over 14 days at refrigeration temperature (6°C) and room temperature (25°C) and over 24 h at body temperature (37°C). Drug concentrations over time were determined by using high-performance liquid chromatography coupled to a mass spectrometer. In addition, drug activity was assessed by a disk diffusion method, diluent stability by visual inspection and drug adsorption by comparison of the measured and calculated concentrations. Blank peritoneal dialysis fluids and deionized water were used as comparator solutions. Fosfomycin was stable in all peritoneal dialysis fluids and at each storage condition investigated over the whole study period. The remaining drug concentrations ranged between 94% and 104% of the respective initial concentrations. No significant drug adsorption was observed for any peritoneal dialysis fluid at any storage condition. No relevant reduction of antimicrobial activity was observed. Fosfomycin is compatible with Extraneal®, Nutrineal® and Physioneal® for up to two weeks at refrigeration or room temperature and may be used for home-based therapy. No dose adjustment is needed due to adsorption or degradation.

show abstract

“…20120323) was supplied by Ningbo Honor Chemtech Co., Ltd., Ningbo, China. Fosfomycin disodium solution has been reported to be stable for both a short period (24 h) and longer periods of up to 14 days ( 54 , 55 ) and to have a long shelf-life (2.9 × 10 7 h) when stored in dry powder form ( 56 ). Moreover, the potency of the powder was regularly reevaluated during the study by agar dilution MIC testing of both a fresh solution and a solution that had been stored overnight at 4°C, and it remained stable.…”

Section: Methodsmentioning

confidence: 99%

Pharmacokinetics and Pharmacodynamics of Fosfomycin and Its Activity against Extended-Spectrum-β-Lactamase-, Plasmid-Mediated AmpC-, and Carbapenemase-Producing Escherichia coli in a Murine Urinary Tract Infection Model

Zykov

Samuelsen

Jakobsen

et al. 2018

Antimicrob Agents Chemother

View full text Add to dashboard Cite

Fosfomycin has become an attractive treatment alternative for urinary tract infections (UTIs) due to increasing multidrug resistance (MDR) in Escherichia coli. In this study, we evaluated the pharmacokinetic (PK) and pharmacodynamic (PD) indices of fosfomycin and its in vivo activity in an experimental murine model of ascending UTI. Subcutaneous administration of fosfomycin showed that the mean peak plasma concentrations of fosfomycin were 36, 280, and 750 mg/liter following administration of a single dose of 0.75, 7.5, and 30 mg/mouse, respectively, with an elimination half-life of 28 min, and urine peak concentrations of 1,100, 33,400, and 70,000 mg/liter expected to be sustained above 1 mg/liter (MIC of the test strain, NU14) for 5, 8, and 9.5 h, respectively. The optimal PK/PD indices for reducing urine colony counts (number of CFU per milliliter) were determined to be the area under the concentration-time curve/MIC from 0 to 72 h and the maximum concentration/MIC on the basis of the dose-dependent bloodstream PK and the results of an evaluation of six dosing regimens. With a dosing regimen of 15 mg/mouse twice (every 36 h), fosfomycin significantly reduced the number of CFU per milliliter of all susceptible strains in urine, including clinical MDR strains, except for one clinical strain (P = 0.062). Variable degrees of reduction were observed in the bladder and kidneys. No significant reductions in the number of CFU per milliliter were observed with the resistant strains. In conclusion, fosfomycin shows concentration-dependent in vivo activity, and the results suggest that fosfomycin is an effective alternative to carbapenems in treating MDR E. coli in uncomplicated UTIs. The data on the effectiveness of fosfomycin against the MDR isolates along with the results of PK/PD modeling should facilitate the further development of improved recommendations for its clinical use.

show abstract

Stability of fosfomycin and qninolones in peritoneal dialysis solution

Cited by 8 publications

References 0 publications

The Combination of Fosfomycin, Metronidazole, and Recombinant Human Granulocyte-Macrophage Colony-Stimulating Factor is Stable in vitro and Has Maintained Antibacterial Activity

The Combination of Fosfomycin, Metronidazole, and Recombinant Human Granulocyte-Macrophage Colony-Stimulating Factor is Stable in vitro and Has Maintained Antibacterial Activity

Compatibility of fosfomycin with different commercial peritoneal dialysis solutions

Pharmacokinetics and Pharmacodynamics of Fosfomycin and Its Activity against Extended-Spectrum-β-Lactamase-, Plasmid-Mediated AmpC-, and Carbapenemase-Producing Escherichia coli in a Murine Urinary Tract Infection Model

Contact Info

Product

Resources

About